Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 115

Therapies Disease Engineering Medical Schools 115

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Chemical Biology and Drug Design

JANUARY 23, 2024

Abstract Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with lipid deposition in liver cells and/or subsequent inflammation, excluding other known causes. At present, the pathogenesis of NAFLD remains unclear. At present, the pathogenesis of NAFLD remains unclear.

Production 100

Production Disease Regulations 100

Chemical Biology and Drug Design

MAY 11, 2023

The figure depicts the neuroprotective role of crocin in Parkinson's disease. Abstract Parkinson's disease is among the most common forms of neurodegenerative illness, with present treatment being primarily symptomatic and frequently coming with substantial adverse effects.

Disease 100

Disease Research Clinical Trials Treatment 100

Fierce BioTech

SEPTEMBER 24, 2024

Unlocking European market access for rare disease therapies The European orphan drug market presents a significant opportunity for biotech firms. Learn more about early access programs (EAPs), and how they are emerging as a critical strategy for successfully launching rare disease therapies in this complex and diverse market.

Marketing 40

Marketing Therapies Disease Drugs 40

BioPharma Drive: Drug Pricing

JUNE 17, 2024

One expert described trial results presented at EULAR last week as “unprecedented.” ” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

Disease 139

Disease Therapies Trials 139

Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. Using humans as the model, we use an approach called deep phenotyping to explore the relationships between cells, genes, biological pathways and patterns of disease. At present, we test discarded human livers deemed not good enough for transplant.

Therapies 102

Therapies Disease RNA Engineering 102

Drug Target Review

JULY 3, 2023

There is a significant unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases. Unfortunately, the majority of genetic diseases lack a cure, leaving limited therapeutic options available.

Disease 98

Disease DNA Therapies Treatment 98

SCIENMAG: Medicine & Health

DECEMBER 5, 2023

The protein TDP-43 is present in all cells of our body and important for their biochemical processes. However, this protein can aggregate into large clumps in the brain, which can cause degenerative diseases such as Alzheimer’s and other dementias.

Disease 85

Disease Research 85

Broad Institute

DECEMBER 7, 2023

When researchers detect two mutations within a particular gene in a patient’s genome, it can be difficult or expensive to determine if those two mutations are present in the same copy of the gene (“in cis ”) or different copies of the gene (“in trans ”). Tags: Medical and Population Genetics Program Rare Disease Clinical genomics

Disease 104

Disease Hospitals International Research 104

Drug Target Review

AUGUST 31, 2023

In the pursuit of a remedy for Alzheimer’s disease, a frontier in medical science is illuminating a glimmer of hope. Chronic inflammation involving microglia has been linked to the disease, as the release of inflammatory molecules triggers an increase in β-amyloid production.

Therapies 105

Therapies Disease Research Treatment 105

Chemical Biology and Drug Design

FEBRUARY 2, 2024

Abstract Existing chemotherapy for neglected tropical diseases (NTDs) can often be toxic and ineffective, highlighting the necessity for new treatments. Their use in combination therapy decreases the concentration of the reference drug used. Terpenes are secondary metabolites with pharmacological potential.

Treatment 100

Treatment Disease Immune Response Therapies 100

SCIENMAG: Medicine & Health

MARCH 5, 2024

WHAT: A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

Disease 68

Disease Clinical Trials Trials 68

The Pharma Data

NOVEMBER 9, 2021

– More than 30 Abstracts Across HDV, HCV, HBV, NASH and PSC Reflect Gilead’s Ongoing Commitment to Addressing Challenges Facing People Living With Liver Diseases –. About Gilead Sciences in Liver Disease. For more than 20 years, Gilead has sought to address some of the biggest challenges in liver disease. Gilead Lores,Inc.

Disease 52

Disease Clinical Trials Treatment Pharmacokinetics 52

SCIENMAG: Medicine & Health

AUGUST 31, 2023

A new blood test called p-tau217 shows promise as an Alzheimer’s disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology.

Disease 87

Disease Research 87

SCIENMAG: Medicine & Health

JUNE 18, 2023

Houston, TX – In a study by a research group at Baylor College of Medicine, oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model. The findings were presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.

Disease 76

Disease Research 76

Conversations in Drug Development Trends

AUGUST 29, 2024

By: Nathan Chadwick, Therapeutic Strategy Lead, Rare Disease Over the last few years in clinical trials, particularly within the rare disease community, a notable shift is underway, where patients and caregivers are taking the lead in reaching out to clinical trial sites rather than the other way around.

Clinical Trials 52

Clinical Trials Trials Disease Drug Development 52

DrugBank

JULY 20, 2023

Rare diseases, therefore, present compelling opportunities for Drug Development. Since each disease is present in small groups of patients, this research is also fraught with complex challenges. We're excited to expand our data offering by launching a new Rare Disease add-on to complement our Clinical Trial dataset.

Disease 74

Disease Clinical Trials Trials FDA 74

Drug Target Review

MAY 7, 2024

Why are biomarkers particularly critical in the context of rare diseases? Developing novel therapeutic approaches for rare diseases poses inherent challenges due to the limited populations available for testing. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

Broad Institute

OCTOBER 23, 2023

By Makenzie Kohler October 23, 2023 People of South Asian ancestry around the world have more than double the risk of developing cardiometabolic diseases like diabetes, heart attack, and stroke compared to other populations.

Disease 145

Disease Research Hospitals DNA 145

SCIENMAG: Medicine & Health

JUNE 16, 2023

CHICAGO—The percent of metabolic associated fatty liver disease (MAFLD), the leading global cause of liver disease, is increasing in U.S. adults, according to a study presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

Disease 65

Disease 65

Chemical Biology and Drug Design

JULY 30, 2023

Abstract Parkinson's disease (PD) is a neurodegenerative disorder that affects 2%–3% of the population worldwide. Clinical presentation of PD includes motor and non-motor symptoms. SG restored striatal histopathological damage and dopamine concentration in rat striatum, and behavioural alterations in rats.

Disease 100

Disease Research 100

ASPET

JANUARY 23, 2024

Patients with sickle cell disease (SCD) display priapism, a prolonged penile erection in the absence of sexual arousal. The current pharmacological treatments for SCD-associated priapism are limited and focused on acute interventions rather than prevention.

Disease 100

Disease Therapies Treatment Research 100

Elrig

APRIL 11, 2024

One of the great highlights of a:head’s work has been the ability to observe disease-specific phenotypes and profile clinically used therapeutics for their ability to alter neuronal network activity. The post How to develop drugs for neurological diseases | Insights from Josh Bagley first appeared on ELRIG.

Disease 59

Disease Drugs Regulations Therapies 59

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? By encapsulating specific self-antigens within our biodegradable nanoparticles, we enable the targeted delivery of the CNPs to antigen-presenting cells (APCs) primarily in the spleen and liver.

Disease 50

Disease Therapies Pharmaceuticals Clinical Trials 50

Fierce BioTech

JULY 12, 2023

Real-World Data for Cardiovascular Disease Research These days, top-tier biopharma companies are using real-world data (RWD) to power their cardiovascular disease research. With so many sources of data, both in-house and licensed, we know it can be hard to sort through it all and analyze what you need to answer your research questions.

Disease 52

Disease Research Licensing Licensing 52

Chemical Biology and Drug Design

APRIL 19, 2023

Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused due to the damage and loss of neurons in specific brain regions. The present work identifies and explains compounds with considerable Acetylcholinesterase (AChE) inhibitory activities. It is the most common form of dementia observed in older people.

Disease 100

Disease Therapies Research Drugs 100

Drug Target Review

JANUARY 24, 2024

Scientists from Northwestern Medicine have demonstrated that RNA interference could have a crucial role in the onset and development of Alzheimer’s disease (AD). Alzheimer’s disease Alzheimer’s is the most common cause of dementia. The team found very short sequences present in some of these sRNAs. Alzheimer’s disease.

RNA 65

RNA Disease DNA Engineering 65

Drugs.com

JANUARY 11, 2024

11, 2024 -- DNA locked in the bones and teeth of more than 5,000 humans who lived in Asia and Europe up to 34,000 years ago are providing vital clues to a myriad of present-day medical conditions.The descendants of these ancient. THURSDAY, Jan.

DNA 98

DNA Disease 98

The Pharma Data

OCTOBER 27, 2020

Cowen Virtual Presentation Series – 2020 IO Next Summit at 1:15 p.m. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. EST on Monday, November 9, 2020. EST on Friday, November 13, 2020. EST ( 12:20 p.m.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

SCIENMAG: Medicine & Health

JANUARY 17, 2024

and colleagues present these findings in the open-access journal PLOS ONE on January 17. A study of more than 25,000 U.S. dogs and 238 breeds has linked dog size to varying patterns of risk for health conditions over the course of a dog’s lifespan. Yunbi Nam of the University of Washington, U.S., On average, smaller […]

Disease 94

Disease 94

SCIENMAG: Medicine & Health

JUNE 9, 2023

Glasgow, UK: Being to identify people at high risk of chronic disease means that they can be targeted with prevention measures before they become sick.

Disease 65

Disease Research 65

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Trials Disease Hospitals 52

The Pharma Data

MAY 14, 2021

Product Name: Free High Blood Pressure Presentation. Click here to get Free High Blood Pressure Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Delivering Hope & Healing, Since 2004.

Testimonials 52

Testimonials Medical Schools Nurses Production 52

Fierce BioTech

SEPTEMBER 11, 2023

Aligning cross-functional teams across the organization to ensure medical, marketing, and market access are all in lock-step is even more crucial when launching a therapy into a rare disease market. png Listing Introduction Herspiegel experts share best practices for addressing the unique aspects of successful rare disease commercialization.

Production 52

Production Disease FDA Approval Therapies 52

biobide

FEBRUARY 2, 2024

Pediatric cancers exhibit differences at the genetic level compared to the same form of adult disease, which may influence the selected treatment. Some pediatric cancers, such as leukemias, present a high survival percentage with the available treatment regimens but cause systemic toxicities, and a subset of patients eventually relapse.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Conversations in Drug Development Trends

APRIL 5, 2024

For others, this rare day is aptly the day we honor rare disease communities. Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services.

Disease 52

Disease Clinical Trials Trials Treatment 52